Visceral Leishmaniasis Treatment, Italy

Visceral Leishmaniasis Treatment, Italy

First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change...

Full description

Bibliographic Details
Main Authors: Luigi Gradoni, Marina Gramiccia, Aldo Scalone
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2003-12-01
Series:Emerging Infectious Diseases
Subjects:
Visceral leishmaniasis
drug treatment
pentavalent antimony
amphotericin B
Italy
Online Access:https://wwwnc.cdc.gov/eid/article/9/12/03-0178_article
Description
Summary:First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
ISSN:1080-6040
1080-6059

Similar Items